.jpg?#)
Aurobindo Pharma Incurring Loss At China Plant, Aims Break-Even By Q4
The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals
The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals
What's Your Reaction?
